Instructions to Authors 2015

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
THE BINAYTARA FOUNDATION
PRESENTS

International Conference on Advances in Hematology and Oncology
August 28-29, 2015

The Coeur d'Alene Resort
Coeur d'Alene, Idaho, USA.
http://oncology.binayfoundation.org

INVITATION TO SUBMIT ABSTRACTS


Accepted abstracts will be published in Anticancer Research

We will accept abstracts in the following categories:

1. Basic science research
2. Clinical research
3. Case reports

E-mail - hemeonc@binayfoundation.org with any question.

Target audience:

- Basic science & clinical researchers
- Hematologists/Oncologists, Surgeons, Radiation oncologists
- Internists, Pharmacists, Nurses, and Others

Why Attend?
High Quality Educational Sessions
Scientific abstract sessions
Networking
Location
Predictive Biomarkers to Chemotherapy in Patients with Advanced Melanoma Receiving the Combination of Cisplatin - Vinblastine -Temozolomide (PVT) as First-line Treatment: A Study of the Hellenic Cooperative Oncology Group (HECOG). H. LINARDOU, G. PENTHEROUDAKIS, I. VARTHALITIS, H. GOGAS, D. PECTASIDES, T. MAKATSORIS, G. FOUNTZILAS, D. BAFALOUKOS (Athens; Ioannina; Hania; Patras; Thessaloniki, Greece) ................................................................. 1105

Cyclin I mRNA Expression Correlates with Kinase Insert Domain Receptor Expression in Human Epithelial Ovarian Cancer. M. CYBULSKI, W. JELENIEWICZ, A. NOWAKOWSKI, A. STENZEL-BEMBENEK, R. TARKOWSKI, J. KOTARSKI, A. STEPULAK (Lublin; Warszawa, Poland) .............................................. 1115


Abstracts of the Christie International Student Cancer Conference 2014 (Manchester, UK) ........................................ 1139

PROCEEDINGS OF THE 5TH INTERNATIONAL SYMPOSIUM ON VITAMIN D AND ANALOGS IN CANCER PREVENTION AND THERAPY, 2-3 May, 2014, Krefeld, Germany ................................................................. 1143-1218

What Do We Learn from the Genome-wide Perspective on Vitamin D₃ (Review)? C. CARLBERG (Kuopio, Finland) ................................................................. 1143

25-Hydroxyvitamin D and Breast Cancer, Colorectal Cancer, and Colorectal Adenomas: Case–Control versus Nested Case–Control Studies (Review). W.B. GRANT (San Francisco, CA, USA) .......................... 1153

Vitamin D in Preventive Medicine (Review). S. PILZ, M. GAKSCH, B. Ó HARTAIGH, A. TOMASCHITZ, W. MÁRZ (Graz; Bad Aussee, Austria; Amsterdam, the Netherlands; New York, NY; New Haven, CT, USA; Mannheim, Germany) ................................................................. 1161

Vitamin D Levels and Dietary Intake Among Patients with Benign Soft Tissue Tumors and Sarcomas. A. JUZENIENE, A.C. POROJNICU, Z. BATURAITE, Z. LAGUNOVA, L. AKNES, Ø.S. BRULAND, J. MOAN (Oslo; Bergen, Norway) ................................................................. 1171

Vitamin D Status and Cancer Prevalence of Hemodialysis Patients in Germany. P. MARQUARDT, R. Krause, M. Schaller, D. Bach, G. Von Gorsdorff (Cologne; Berlin; Neu-Isenburg, Germany) ................................................................. 1181

Combined Treatment of Breast Cancer Cell Lines with Vitamin D and COX-2 Inhibitors. M. Thill, K. Reichert, A. Woeste, S. Polack, D. Fischer, F. Hoellen, A. Rody, M. Friedrich, F. Köster (Frankfurt; Lübeck; Krefeld, Germany) ................................................................. 1189

Vitamin D Inhibits Ovarian Cancer Cell Line Proliferation in Combination with Celecoxib and Suppresses Cyclooxygenase-2 Expression. M. Thill, A. Woeste, K. Reichert, D. Fischer, A. Rody, M. Friedrich, F. Köster (Frankfurt; Lübeck; Krefeld, Germany) ................................................................. 1197

Development of Efficient Chemical Syntheses of Vitamin D Degradation Products. L. Kattner, D. Bernardi, E. Rauch (Saarbrücken, Germany) ................................................................. 1205

Effect of Serum Cotinine on Vitamin D Serum Concentrations Among American Females with Different Ethnic Backgrounds. K.R. Manavi, B.P. Alston-Mills, M.P. Thompson, J.C. Allen (Raleigh, NC; East Lansing, MI, USA) ................................................................. 1211

Errata ......................................................................................................................... 1219

Book Reviews ........................................................................................................... 1221

Announcements ...................................................................................................... 1228
Preoperative Serum Methylation Signature as Prognostic Tool After Curative Hepatectomy in Patients with Hepatocellular Carcinoma. S. KANEKIYO, N. IIZUKA, R. TSUNEDOMI, Y. TOKUMITSU, N. HASHIMOTO, Y. TOKUHISA, Y. MAEDA, M. IIDA, K. SAKAMOTO, T. TAMESA, Y. FUJITA, S. YOSHINO, S. HAZAMA, Y. HAMAMOTO, M. OKA (Ube, Yamaguchi, Japan) ........................................ 997

Correlation Between $^{18}$F-FDG-uptake and In Vitro Chemosensitivity of Cisplatin in Head and Neck Cancer. H. SUZUKI, M. NISHIO, N. HANAI, H. HIRAKAWA, T. TAMAKI, Y. HASEGAWA (Nagoya, Japan) ................. 1009

Improving the Prediction of Pathologic Outcomes in Patients Undergoing Radical Prostatectomy: The Value of Prostate Cancer Antigen 3 (PCA3), Prostate Health Index (Phi) and Sarcosine. M. FERRO, G. LUCARELLI, D. BRUZZESE, S. PERDONÀ, C. MAZZARELLA, G. PERRUOLO, A. MARINO, V. COSIMATO, E. GIORGIO, V. TAGLIAMONTE, D. BOTTERO, O. DE COBELLI, D. TERRACCIANO (Milan; Bari; Naples, Italy) ............................................................................................................ 1017


Lymphatic and Blood Vessels in Male Breast Cancer. J. NIEMIEC, B. SAS-KORCZYNSKA, A. HARAZIN-LECHOWSKA, D. MARTYNOW, A. ADAMCYK (Krakow, Poland) ......................................................... 1041


Predictive Factors for Response to Abiraterone in Metastatic Castration Refractory Prostate Cancer. M. AFSHAR, F. AL-ALLOOSH, S. PIRRIE, C. ROWAN, N.D. JAMES, E. PORFIRI (Birmigham; Warwick, UK) ............. 1057

Difference in Benefit of Chemotherapy Between Small Cell Lung Cancer Patients with Interstitial Pneumonia and Patients with Non-small Cell Lung Cancer. K. KASHIWABARA, H. SEMBA, S. FUJII, S. TSUMURA, R. AOKI (Kumamoto, Japan) .............................................................. 1065


Alteration of miRNA Expression Correlates with Lifestyle, Social and Environmental Determinants in Esophageal Carcinoma. É. STÁNITZ, K. JUHÁSZ, K. GOMBOS, K. GÓCZE, C. TÓTH, I. KISS (Szombathely; Pécs, Hungary) .................................................. 1091

Correlation Between CA125 Levels After Sixth Cycle of Chemotherapy and Clinical Outcome in Advanced Ovarian Carcinoma. A. GADDUCCI, A. MENICETTI, I. GUIGGI, M. NOTARNICOLA, S. COSIO (Pisa, Italy) ........................................................................................................................................ 1099

Contents continued on the preceding page
Survival Outcome of Borrmann Type IV Gastric Cancer Potentially Improved by Multimodality Treatment. K. YAMASHITA, K. HOSODA, N. KATADA, H. MORIYA, H. MIENO, K. HIGUCHI, T. SASAKI, C. KATADA, S. SAKURAMOTO, S. TANABE, W. KOIZUMI, S. KIKUCHI, M. WATANABE (Sagamihara, Kanagawa; Hidaka, Saitama, Japan) .................................................. 897


Age Influences the Clinical Significance of Atypical Glandular Cells on Cytology. K.C. ASCIUTTO, E. HENIC, O. FORSLUND, K. BJELKENKRANTZ, C. BORGFELDT (Lund, Sweden) .............................................................. 913

VEGFR3 and CD31 as Prognostic Factors in Renal Cell Cancer. J. VIRMAN, P. BONO, T. LUUKKAALA, K. SUNELA, P. KUJALA, P.-L. KELLOKUMPU-LEHTINEN (Tampere; Helsinki, Finland) ......................... 921

β-Catenin Helices in the Cytoplasm of Sessile Serrated Adenoma/Polyps and Conventional Colorectal Adenomas. C.A. RUBIO, A. KAUFELDT, R. KOHA, M. USHOIDA, J. LINDAHL, L.L. KIS (Stockholm, Sweden) ............... 929

Radiobiological Treatment Planning Evaluation of Inverse Planning Simulated Annealing for Cervical Cancer High-dose-rate Brachytherapy. T. PALMQVIST, L. DOS S. MATIAS, A.B.L. MARTHINSEN, M. SUNDSET, A.D. WANDERÅS, S. DANIelsen, I. TOMA-DASU (Stockholm, Sweden; Maputo, Mozambique; Trondheim, Norway) ........................................................................................................... 935

The Relation of Hopelessness/Helplessness versus Beck Depression Inventory (BDI) in Healthy Individuals and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case-control Study in Finland. M. ESKE LINEN, R. KORHONEN, T. SELANDER, P. OLLONEN (Kuopio, Finland) .................................................. 941

Low PHLD A3 Expression in Oesophageal Squamous Cell Carcinomas Is Associated with Poor Prognosis. H. MUROI, M. NAKAJIMA, H. SATOMURA, M. TAKAHASHI, S. YAMAGUCHI, K. SASAKI, T. YOKOBORI, T. MIYAZAKI, H. KUWANO, H. KATO (Tochigi; Gunma, Japan) ................................................................. 949

Assessment of Grading in Newly-diagnosed Glioma Using 18F-Fluorothymidine PET/CT. E. FERDOVÁ, J. FERDA, J. BAXA, R. TUPÝ, J. MRAČEK, O. TOPOĽČAN, O. HES (Plzeň, Czech Republic) .................. 955


FDG PET/CT and MR Imaging of CD34-Negative Soft-tissue Solitary Fibrous Tumor with NAB2-STAT6 Fusion Gene. J. NISHIO, H. IWASAKI, M. AOKI, K. NABESHIMA, M. NAITO (Fukuoka, Japan) ................................................................. 967

Claudin-5 Is Associated with Elevated TATI and CA125 Levels in Mucinous Ovarian Borderline Tumors. R. NISSI, A. TALVENSAA RIMATTILA, P. KUVAJA, P. PÄÄKKÖ, Y. SOINI, M. SANTALA (Oulu; Kuopio, Finland) ................................................................. 973

Feasibility Study of Alternate-day S-1 as Adjuvant Chemotherapy for Head and Neck Cancer. Y. MORO, Y. KOGASHIWA, D. SATO, Y. MATSUMOTO, T. NAKAMURA, K. YAMAUCHI, H. SAKURAI, N. KOHNO (Tokyo; Hidaka, Saitama, Japan) ................................................................. 977

Prognostic Factors in Cancer Patients with Symptomatic Pituitary Metastasis: A Clinical Case Study. C.-Y. LIN, W.-K. HUANG, F.-T. CHUNG, H.-K. CHANG (Taoyuan, Taiwan, ROC) ................................................................. 983

Left Ventricular Systolic Dysfunction in Metastatic Breast Cancer Patients: A Polish Multicenter Registry. S. SZMIT, J. STREB, W. STARZEC, D. ZUZIAK, M. WIATKOWSKI, B. CZARTORYSKA-ARŁUKOWICZ, D. IZYCKI, A. ŚMIALOWSKA-JANISZEWSKA, J. HANS LIK, A. BRYJAK, M. TALERZYK, J.M. ZAUCHA (Otwock; Cracow; Bydgoszcz; Bialystok; Poznań; Łódź; Racibórz; Szczecin; Gdynia, Poland) ........................................................................................................... 989

Contents continued on the preceding page
Comparative Effects of 4-Phenyl-3-Butenoic Acid and Vorinostat on Cell Growth and Signaling. T.J. BURNS, A. ALI, D.F. MATESIC (Atlanta, GA, USA) .......................................................... 775

Prolyl Isomerase PIN1 Negatively Regulates SGK1 Stability to Mediate Tamoxifen Resistance in Breast Cancer Cells. A. JO, H.J. YUN, J.Y. KIM, S.-C. LIM, H.J. CHOI, B.S. KANG, B.-Y. CHOI, H.S. CHOI (Gwangju; Daegu; Cheongju, Republic of Korea) .......................................................... 785

Cantharidin Induces DNA Damage and Inhibits DNA Repair-associated Protein Expressions in TSGH8301 Human Bladder Cancer Cell. J.-H. KUO, T.-Y. SHIH, J.-P. LIN, K.-C. LAI, M.-L. LIN, M.-D. YANG, J.-G. CHUNG (Taiichung; Yunlin, Taiwan, ROC) .................................................. 795

Vitamin D Effect on Growth and Vitamin D Metabolizing Enzymes in Triple-negative Breast Cancer. S.E. RICHARDS, K.A. WEIERSTAHL, J.L. KELTS (Flint, MI, USA) .......................................................... 805

Synthesis and Structure–Activity Relationship Studies of Furan-ring Fused Chalcones as Antiproliferative Agents. Y. SAITO, M. KISHIMOTO, Y. YOSHIZAWA, S. KAWAI (Hatoyama, Saitama; Akita, Japan) ...... 811

The Role of KISS1/KISS1R System in Tumor Growth and Invasion of Differentiated Thyroid Cancer. C. SAVVIDIS, E. PAPAOICONOMOU, C. PETRAKI, P. MSAOUEL, M. KOUTSILIERIS (Athens, Greece; Bronx, NY, USA) .......................................................... 819

Langmuir-Blodgett (LB)-based Nanobiocrystallography at the Frontiers of Cancer Proteomics. E. PECHKOVA, N.L. BRAGAZZI, S. FIORDORO, C. NICOLINI (Bergamo; Genova, Italy; Grenoble, France) .................. 827

In Vitro Efficacy of Cinnarizine Against Lymphoma and Multiple Myeloma. L.C. SCHMEEL, F.C. SCHMEEL, Y. KIM, S. BLAUM-FEDER, T. ENDO, I.G.H. SCHMIDT-WOLF (Bonn, Germany; Sapporo, Japan) ........... 835


Human Papillomavirus and Breast Cancer: No Evidence of Association in a Spanish Set of Cases. M. VERNET-TOMAS, M. MENA, L. ALEMAN, I. BRAVO, S. DE SANJOSÉ, P. NICOLAU, A. BERGUEIRO, J.M. COROMINAS, S. SERRANO, R. CARRERAS, B. LLOVERAS (Barcelona; L Hospitalet de Llobregat, Spain) .................................................................................................................. 851


Clinical Studies

Macrophage-Colony Stimulating Factor (CSF1) Predicts Breast Cancer Progression and Mortality. E. RICHARDSEN, R. DALE UGLEHUS, S.H. JOHNSEN, L.-T. BUSUND (Tromsø, Norway) ............................. 865

Rare Case of a Primary Intracranial Chondrosarcoma. E. SMOLLE, M. MOYR, J. HAYBAECK (Graz, Austria) .................................................................................................................. 875

Proteomic Identification of Autoantibodies in Sera from Patients with Ovarian Cancer as Possible Diagnostic Biomarkers. K. YONEYAMA, S. KOJIMA, Y. KODANI, N. YAMAGUCHI, A. IGARASHI, K. KUROSE, R. KAWASE, T. TAKESHITA, S. HATTORI, K. NAGATA (Tokyo; Saitama, Japan) .................. 881


Contents continued on the preceding page
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complementarity of Variable-magnification and Spectral-separation Fluorescence Imaging Systems for Noninvasive Detection of Metastasis and Intravital Detection of Single Cancer Cells in Mouse Models. Y. ZHANG, Y. HIROSHIMA, H. MA, N. ZHANG, M. ZHAO, R.M. HOFFMAN (San Diego, CA, USA; Yokohama, Japan)</td>
<td>661</td>
</tr>
<tr>
<td>GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray. J.W. RIESS, R. WEST, M. DEAN, A.C. KLIMOWICZ, J.W. NEAL, C. HOANG, H.A. WAKEEL (Sacramento; Stanford, CA, USA; Alberta, Canada)</td>
<td>669</td>
</tr>
<tr>
<td>Expression of xCT as a Predictor of Disease Recurrence in Patients with Colorectal Cancer. K. SUGANO, K. MAEDA, H. OHTANI, H. NAGAHARA, M. SHIBUTANI, K. HIRAKAWA (Osaka, Japan)</td>
<td>677</td>
</tr>
<tr>
<td>Involvement of mTOR Signaling Pathways in Regulating Growth and Dissemination of Metastatic Brain Tumors via EMT. A. KWASNICKI, D. JEEVAN, A. BRAUN, R. MURALI, M. JHANWAR-UNIYAL (Valhalla, NY, USA)</td>
<td>689</td>
</tr>
<tr>
<td>Tumor Progression Is Associated with Increasing CD11b+ Cells and CCL2 in Lewis Rat Sarcoma. R. MISHRA, J. KOVALSKA, J. JANDA, L. VANNUCCI, R. RAJMON, V. HORAK (Libechov; Prague, Czech Republic)</td>
<td>703</td>
</tr>
<tr>
<td>Treatment of Transmissible Veneral Tumors in Dogs with Intratumoral Interleukin-2 (IL-2). A Pilot Study. W. DEN OTTER, M. HACK, J.J.L. JACOBS, J.F.V. TAN, L. ROZENDAAL, R.J.A. VAN MOORSELAAR (Amsterdam; Curaçao; Gouda, the Netherlands)</td>
<td>713</td>
</tr>
<tr>
<td>MicroRNA Profiles to Predict Postoperative Prognosis in Patients with Small Cell Carcinoma of the Esophagus. T. OKUMURA, Y. SHIMADA, T. OMURA, K. HIRANO, T. NAGATA, K. TSUKADA (Toyama; Kyoto, Japan)</td>
<td>719</td>
</tr>
<tr>
<td>Cantharidin Impairs Cell Migration and Invasion of A375.S2 Human Melanoma Cells by Suppressing MMP-2 and -9 Through PI3K/NF-κB Signaling Pathways. B.-C. JI, Y.-P. HSIAO, C. H. TSAI, S.-J. CHANG, S.-C. HSU, H.-C. LIU, Y.-P. HUANG, J.-C. LIEN, J.-G. CHUNG (Changhua; Taichung, Taiwan, ROC)</td>
<td>729</td>
</tr>
<tr>
<td>Renal Fibrogenesis and Platinum Compounds in a Rat Model: A Novel Pt (II) Complex vs. Cisplatin. C. FENOGLO, F. ALBICINI, S.A. DE PASCALI, G. MILANESI, M. FUMAGALLI, D. MIGONI, F.P. FANIZZI, G. BERNOCHI (Pavia; Lecce, Italy)</td>
<td>739</td>
</tr>
<tr>
<td>Multi-Responsive Polymer Micelles as Ellipticine Delivery Carriers for Cancer Therapy. M. STUDENOVSKY, O. SEDLACEK, M. HRUBY, J. PANEK, K. ULBRICH (Prague, Czech Republic)</td>
<td>753</td>
</tr>
<tr>
<td>Differential Expression of E-Cadherin in Primary Breast Cancer and Corresponding Lymph Node Metastases. V. FULGA, L. RUDICO, A.R. BALICA, A.M. CIMPEAN, L. SAPTEFRATI, M.-M. MARGAN, M. RAICA (Chisinau, Republic of Moldova; Timisoara, Romania)</td>
<td>759</td>
</tr>
<tr>
<td>Resveratrol Induces Apoptosis and Alters Gene Expression in Human Fibrosarcoma Cells. K. HARATI, P. SLODNIK, A.M. CHROMIK, O. GOERTZ, T. HIRSCH, N. KAPALHSINSKI, L. KLEIN-HITPASS, J. KOLBENSCHLAG, W. UHL, M. LEHNHARDT, A. DAIGELER (Bochum; Essen, Germany)</td>
<td>767</td>
</tr>
</tbody>
</table>